| Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity A Moeini, D Sia, Z Zhang, G Camprecios, A Stueck, H Dong, R Montal, ... Journal of hepatology 66 (5), 952-961, 2017 | 141 | 2017 |
| Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification C Montironi, F Castet, PK Haber, R Pinyol, M Torres-Martin, L Torrens, ... Gut, 2022 | 111 | 2022 |
| Immunomodulatory effects of lenvatinib plus anti–programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma L Torrens, C Montironi, M Puigvehí, A Mesropian, J Leslie, PK Haber, ... Hepatology 74 (5), 2652-2669, 2021 | 107* | 2021 |
| Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications J Carrillo-Reixach, L Torrens, M Simon-Coma, L Royo, M Domingo-Sàbat, ... Journal of hepatology 73 (2), 328-341, 2020 | 86 | 2020 |
| Liver injury increases the incidence of HCC following AAV gene therapy in mice DA Dalwadi, L Torrens, J Abril-Fornaguera, R Pinyol, C Willoughby, ... Molecular Therapy 29 (2), 680-690, 2021 | 75 | 2021 |
| Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma L Bassaganyas, R Pinyol, R Esteban-Fabró, L Torrens, S Torrecilla, ... Clinical Cancer Research 26 (23), 6350-6361, 2020 | 42 | 2020 |
| Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma R Esteban-Fabró, CE Willoughby, M Piqué-Gili, C Montironi, ... Clinical Cancer Research 28 (11), 2449-2460, 2022 | 41 | 2022 |
| Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma J Abril-Fornaguera, L Torrens, C Andreu-Oller, J Carrillo-Reixach, ... Molecular cancer therapeutics 22 (4), 485-498, 2023 | 5 | 2023 |
| Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents L Torrens, M Puigvehí, M Torres-Martín, H Wang, M Maeda, PK Haber, ... Clinical Cancer Research 28 (20), 4509-4520, 2022 | 4 | 2022 |
